Sorrento Therapeutics, Inc. Announces Its Approach to Developing Human Antibody Therapeutics Against MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
5/20/2013 9:59:52 AM
More...
|
Sorrento Therapeutics, Inc. and IGDRASOL Announce the Acquisition of Exclusive Distribution Rights to Cynviloq™ for the European Union
5/14/2013 9:04:15 AM
More...
|
Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
4/8/2013 6:12:02 AM
More...
|
Sorrento Therapeutics, Inc. and IGDRASOL Announce Three Presentations on Cynviloq™ (IG-001; Paclitaxel Polymeric Micelle) at the American Association for Cancer Research (AACR) Meeting
4/1/2013 9:35:09 AM
More...
|
Sorrento Therapeutics, Inc. Signs Exclusive Option to Acquire IGDRASOL
3/7/2013 10:19:03 AM
More...
|
Sorrento Therapeutics, Inc. Acquires Rights to Produce Recombinant Intravenous Immunoglobulins (rIVIG)
1/8/2013 9:36:06 AM
More...
|
Sorrento Therapeutics, Inc. Awarded Third Phase I STTR Grant
6/8/2012 10:41:02 AM
More...
|
Sorrento Therapeutics, Inc. Awarded Phase I STTR Grant for C. difficile Program
7/29/2011 10:10:06 AM
More...
|
Sorrento Therapeutics, Inc.' Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy And Infectious Diseases (NIAID)
7/6/2011 5:56:01 AM
More...
|
Sorrento Therapeutics, Inc. Awarded National Institutes of Health (NIH) Grant for MRSA Program
5/21/2010 10:25:28 AM
More...
|
|